Nabeel Bardeesy Selected Research

futibatinib

10/2021	FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma.
1/2019	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nabeel Bardeesy Research Topics

Disease

93	Neoplasms (Cancer) 04/2022 - 01/2002
22	Pancreatic Neoplasms (Pancreatic Cancer) 04/2022 - 06/2008
18	Adenocarcinoma 01/2022 - 06/2004
15	Cholangiocarcinoma 01/2022 - 04/2014
12	Carcinogenesis 11/2019 - 10/2003
11	Neoplasm Metastasis (Metastasis) 04/2022 - 04/2006
9	Lung Neoplasms (Lung Cancer) 11/2021 - 01/2008
7	Fibrosis (Cirrhosis) 01/2021 - 04/2014
6	Hypoxia (Hypoxemia) 01/2022 - 03/2008
5	Peutz-Jeghers Syndrome (Polyposis, Hamartomatous Intestinal) 01/2019 - 07/2004
4	Hepatocellular Carcinoma (Hepatoma) 01/2020 - 04/2014
3	Disease Progression 10/2021 - 03/2010
3	Inflammation (Inflammations) 11/2014 - 07/2011
3	Polyps 02/2014 - 07/2004
2	Carcinoma (Carcinomatosis) 01/2022 - 01/2008
2	Biliary Tract Neoplasms (Biliary Tract Cancer) 10/2021 - 01/2016
2	Liver Diseases (Liver Disease) 01/2021 - 04/2014
2	Non-alcoholic Fatty Liver Disease 01/2021 - 01/2019
2	Tuberous Sclerosis (Bourneville's Disease) 01/2019 - 07/2004
2	Circulating Neoplastic Cells 01/2019 - 09/2014
2	Liver Neoplasms (Liver Cancer) 01/2018 - 09/2014
2	Hypersensitivity (Allergy) 01/2016 - 08/2013
2	Mitochondrial Diseases (Mitochondrial Disease) 08/2015 - 12/2010
2	Liver Cirrhosis (Hepatic Cirrhosis) 08/2015 - 04/2014
2	Melanoma (Melanoma, Malignant) 01/2015 - 05/2005
2	Colonic Neoplasms (Colon Cancer) 03/2012 - 03/2006
1	Stomach Neoplasms (Stomach Cancer) 12/2021

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2006
12	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2004
10	Biological ProductsIBA 04/2017 - 07/2004
9	Phosphotransferases (Kinase)IBA 10/2021 - 03/2004
8	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2022 - 01/2014
5	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 06/2004
5	Cyclin-Dependent Kinase Inhibitor p16IBA 07/2014 - 01/2002
5	Biomarkers (Surrogate Marker)IBA 04/2014 - 01/2009
5	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 08/2013 - 03/2004
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 01/2015
4	MicroRNAs (MicroRNA)IBA 01/2022 - 09/2011
4	ChromatinIBA 01/2022 - 08/2009
4	Adenosine Triphosphate (ATP)IBA 12/2021 - 07/2004
4	Pharmaceutical PreparationsIBA 01/2021 - 09/2012
4	AMP-Activated Protein KinasesIBA 01/2019 - 03/2004
4	alpha-hydroxyglutarateIBA 09/2014 - 01/2014
3	Transcription Factors (Transcription Factor)IBA 01/2022 - 03/2008
3	infigratinibIBA 12/2021 - 01/2017
3	CollagenIBA 01/2020 - 09/2012
3	Mechanistic Target of Rapamycin Complex 1IBA 12/2016 - 05/2010
3	Messenger RNA (mRNA)IBA 10/2016 - 01/2010
3	ErbB Receptors (EGF Receptor)IBA 04/2014 - 05/2005
3	NucleotidesIBA 08/2013 - 01/2009
3	Peptides (Polypeptides)IBA 09/2012 - 01/2009
3	Transforming Growth Factor beta (TGF-beta)IBA 07/2009 - 11/2006
3	Adenosine Monophosphate (AMP)IBA 02/2008 - 03/2004
2	CytokinesIBA 04/2022 - 07/2011
2	InterferonsIBA 01/2022 - 01/2019
2	EnzymesIBA 01/2022 - 01/2014
2	LigandsIBA 12/2021 - 01/2010
2	futibatinibIBA 10/2021 - 01/2019
2	AlbuminsIBA 01/2021 - 12/2015
2	Contrast MediaIBA 01/2020 - 08/2010
2	folfirinoxIBA 01/2020 - 01/2018
2	Serine (L-Serine)FDA Link 11/2019 - 11/2016
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 01/2017
2	Antiviral Agents (Antivirals)IBA 01/2019 - 11/2014
2	Glutamine (L-Glutamine)FDA Link 01/2019 - 04/2013
2	trans-sodium crocetinate (crocetin)IBA 01/2019 - 07/2004
2	Polycomb Repressive Complex 2IBA 01/2017 - 01/2017
2	Sorafenib (BAY 43-9006)FDA Link 01/2017 - 05/2015
2	Sirolimus (Rapamycin)FDA Link 12/2016 - 03/2010
2	Mechanistic Target of Rapamycin Complex 2IBA 12/2016 - 01/2015
2	Cysteine (L-Cysteine)FDA Link 10/2016 - 01/2009
2	AntioxidantsIBA 10/2016 - 07/2011
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2016 - 07/2015
2	Glucose (Dextrose)FDA LinkGeneric 08/2015 - 10/2009
2	Carbon Tetrachloride (Tetrachloromethane)IBA 08/2015 - 04/2014
2	Oxygen (Dioxygen)IBA 06/2015 - 08/2010
2	Small Interfering RNA (siRNA)IBA 03/2015 - 03/2006
2	Hyaluronic Acid (Hyaluronan)IBA 07/2014 - 09/2012
2	Epidermal Growth Factor (EGF)IBA 04/2014 - 05/2005
2	Insulin (Novolin)FDA Link 03/2014 - 04/2009
2	Complementary DNA (cDNA)IBA 01/2014 - 06/2004
2	CateninsIBA 01/2013 - 03/2012
2	Metformin (Glucophage)FDA LinkGeneric 05/2010 - 12/2005
2	MTOR InhibitorsIBA 03/2010 - 07/2004
2	ProteomeIBA 01/2009 - 06/2008
1	Drug CombinationsIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Glycogen Synthase (Synthase I)IBA 01/2022
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 12/2021
1	3' Untranslated Regions (3' UTR)IBA 11/2021
1	ivosidenibIBA 06/2021
1	Histamine Receptors (Histamine Receptor)IBA 01/2021
1	Nizatidine (Axid)FDA LinkGeneric 01/2021
1	Collagen Type I (Type I Collagen)IBA 01/2020
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2020

Therapy/Procedure

26	Therapeutics 01/2022 - 03/2004
6	Drug Therapy (Chemotherapy) 01/2022 - 04/2010
3	Chemoprevention 01/2021 - 01/2014
3	Immunotherapy 01/2016 - 09/2012
2	Ligation 04/2014 - 01/2009